Tao Xiaogang, Dong Jinqian, Hou Zonggang, Hao Shuyu, Zhang Junting, Wu Zhen, Liu Baiyun
Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China.
Department of Neurosurgery, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China; Nerve Injury and Repair Center of Beijing Institute for Brain Disorders, Beijing, China; Neurotrauma Laboratory, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Beijing Key Laboratory of Central Nervous System Injury, Beijing, China.
World Neurosurg. 2018 Mar;111:e880-e887. doi: 10.1016/j.wneu.2017.12.173. Epub 2018 Jan 8.
Intracranial and intraspinal clear cell meningiomas (CCMs) are rarely reported because of their extremely low incidence, and the current understanding of CCM is poor. The purpose of this study was to analyze the incidence and the clinical, radiologic, pathologic, and prognostic features of intracranial and intraspinal CCMs.
Among 14,310 cases of intracranial and intraspinal meningiomas that were surgically treated between 2006 and 2016 at Beijing Tian Tan Hospital, 56 were chosen for analysis and retrospectively reviewed. To determine which parameters were associated with longer progression-free survival (PFS) and overall survival (OS), statistical analysis was performed.
CCMs accounted for approximately 0.39% of all intracranial and intraspinal meningiomas. Patients with CCM had a mean age of 32.3 years and there was a female predilection (20 males and 36 females). Gross total resection was achieved in 35 cases, and subtotal resection was achieved in 21 cases. All patients were followed up for 10-206 months after surgery. Twenty-six patients experienced tumor recurrence, and the median PFS was 48.0 months. The 1-year, 3-year, and 5-year PFS was 87.5%, 59.8%, and 41.8%, respectively. Twelve patients died of tumor recurrence, and the median OS was not available. The 1-year, 3-year, and 5-year OS was 98.2%, 91.3%, and 65.8%, respectively. Univariate analysis showed that total tumor removal was significantly associated with a better prognosis. Multivariate analysis confirmed only Simpson grade III and IV resection as an independent risk factor for shorter PFS. Radiotherapy mildly improved PFS after both gross total resection and subtotal resection, showing no significant difference because of the small sample size and short follow-up duration.
CCM is a rare subtype of World Health Organization grade II meningioma. CCM typically involves young patients and shows a female predilection and high recurrence rate. When possible, total resection is the primary and most suitable treatment for CCM. For patients with primary tumors, radiotherapy is recommended after the initial operation regardless of the extent of resection. For patients with disease recurrence, secondary surgery combined with radiotherapy might serve as an effective treatment.
颅内和脊髓透明细胞型脑膜瘤(CCM)因其发病率极低,鲜有报道,目前对其认识不足。本研究旨在分析颅内和脊髓CCM的发病率以及临床、影像学、病理学和预后特征。
选取2006年至2016年在北京天坛医院接受手术治疗的14310例颅内和脊髓脑膜瘤患者,其中56例入选并进行回顾性分析。为确定哪些参数与更长的无进展生存期(PFS)和总生存期(OS)相关,进行了统计分析。
CCM约占所有颅内和脊髓脑膜瘤的0.39%。CCM患者的平均年龄为32.3岁,女性居多(男性20例,女性36例)。35例实现了肿瘤全切,21例实现了次全切。所有患者术后随访10 - 206个月。26例患者出现肿瘤复发,中位PFS为48.0个月。1年、3年和5年PFS分别为87.5%、59.8%和41.8%。12例患者死于肿瘤复发,中位OS无法得出。1年、3年和5年OS分别为98.2%、91.3%和65.8%。单因素分析显示肿瘤全切与较好的预后显著相关。多因素分析仅证实辛普森III级和IV级切除是PFS较短的独立危险因素。放疗在肿瘤全切和次全切后均轻度改善了PFS,但由于样本量小和随访时间短,差异无统计学意义。
CCM是世界卫生组织II级脑膜瘤的一种罕见亚型。CCM通常累及年轻患者,女性居多,复发率高。可能的情况下,全切是CCM的主要且最合适的治疗方法。对于原发性肿瘤患者,无论切除范围如何,建议在初次手术后进行放疗。对于疾病复发的患者,二次手术联合放疗可能是一种有效的治疗方法。